Compare Axogen Inc (AXGN) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs J M Smucker Co — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while J M Smucker Co trades at $117.46 (market cap $12.54B). The key difference: J M Smucker Co is far larger — about 4.8× Axogen Inc's market cap, and J M Smucker Co pays a 3.82% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | SJM | |
|---|---|---|
Market Cap | $2.61B | $12.54B |
Sector | Technology | Consumer Staples |
52-Week High | $48.48 | $126.35 |
52-Week Low | $14.16 | $89.53 |
Enterprise Value | $2.52B | $19.57B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
SJM trades at $118.79, up 0.61% today, with a bullish technical signal and analyst consensus price target of $125.11. Recent earnings have shown beats in Q4 2025 and Q1 2026, but the company reported a net loss of $1.23B in 2025, with negative profit margins and ROE. Cash flow from operations remains strong at $1.21B, supporting a dividend increase to $1.12 per share, marking 25 consecutive years of growth. The stock is supported by positive media coverage highlighting value and growth potential.
The outlook is mixed; strong cash flow and dividend growth provide stability, but profitability challenges and high debt levels pose risks. Analyst sentiment is predominantly buy-rated, suggesting upside potential, though investors must weigh fundamental weaknesses against technical and sentiment positives for balanced decision-making.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
